Showing posts with label swine influenza. Show all posts
Showing posts with label swine influenza. Show all posts

Thursday, April 9, 2026

Genetic characterization of a novel triple - #reassortant #influenza #H1N2 virus from #pigs, #China, 2021

 


Abstract

Swine influenza virus (SIV) is a highly contagious respiratory pathogen in pigs, with bidirectional transmission posing a potential threat to human health. In this study, nasal swab samples were collected from pigs in Shandong Province, China, and yielded an H1N2 SIV strain, designated A/swine/Shandong/QD726/2021 (H1N2). Whole-genome sequencing was performed for Sw/SD/QD726/2021, and phylogenetic analysis was conducted together with 156 Chinese H1N2 reference sequences obtained from the Global Initiative on Sharing All Influenza Data (GISAID) database and the National Center for Biotechnology Information (NCBI) Influenza Virus Resource database. The results indicated that Sw/QD726/2021 represents a novel reassortant genotype (G21), with the HA gene derived from Eurasian avian-like H1N1 (EA H1N1), the NA and NS genes from triple-reassortant H1N2 (TR H1N2), and the remaining internal genes (PB2, PB1, PA, NP, M) from the 2009 pandemic H1N1 (pdm/09 H1N1). Key amino acid analysis revealed N31 in M2, responsible for adamantane resistance, and S42 in NS1, which influences viral virulence in mouse models. BALB/c mouse experiments demonstrated efficient viral replication in the lungs and nasal turbinates, accompanied by moderate body weight loss and lung lesions, indicating only moderate pathogenicity. These findings underscore the ongoing evolution of H1N2 SIV in pigs and emphasize the importance of enhanced surveillance and preventive strategies to mitigate public health risks.

Source: 


Link: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1779293/full

____

Thursday, February 19, 2026

Impact of an #aminoacid #deletion detected in the #hemagglutinin (HA) #antigenic site of swine #influenza A virus field strains on HA antigenicity

 


ABSTRACT

Swine influenza A virus (swIAV) is an important pathogen with regard to both the swine industry and public health. The pandemic A(H1N1) 2009 outbreak was caused by the swine-origin pandemic A(H1N1) 2009 [A(H1N1)pdm09] virus. Several reports have shown that several amino acid substitutions in the hemagglutinin (HA) antigenic sites can alter HA antigenicity. However, the impact of the amino acid deletion at position 155 on HA antigenicity remains unknown. In this study, we have isolated 11 samples of swIAVs from seven pig farms in Japan and found an amino acid deletion at position 155 of the HA region in one of the isolates of the H1N2 subtype. To examine the impact of this amino acid deletion on viral replication and HA antigenicity, we generated recombinant influenza A viruses possessing the H1 HA gene encoding either an artificial insertion or deletion of glycine at position 155. The growth kinetics of these recombinant viruses in two different cell lines demonstrated that the effect of amino acid deletion at position 155 of H1 HA on viral replication is limited. In contrast, microneutralization assay-based neutralization titers revealed that amino acid deletion significantly altered HA antigenicity. These results demonstrate that a naturally occurring amino acid deletion at position 155 in an H1 HA antigenic site can markedly alter HA antigenicity with only a limited impact on replication in vitro, highlighting the need to monitor such variants in swine populations and to assess their zoonotic potential.

Source: 


Link: https://journals.asm.org/doi/full/10.1128/jvi.01820-25?af=R

____

Thursday, February 12, 2026

Characterization of a reassortant #H3N2 swine #influenza virus with 2009 pandemic internal #genes and enhanced potential for zoonotic #risk

 


Highlights

• A swine influenza virus H3N2 subtype was isolated during epidemiological survey.

• It is a complex and novel reassortant, and acquired accumulation of adaptive mutations.

• Both rescue and parent strains demonstrated efficient replication in mammalian cells.

• Key residues of the H3N2 HA collectively enhance the binding preference for human-type receptor.

• The rescued H3N2 cause significant pulmonary pathological damage in mice.


Abstract

Pigs serve as key "mixing vessels" for influenza A viruses, playing a critical role in cross-species transmission, while the H3N2 subtype represents an important lineage within the swine influenza virus (SIV) family. In this study, a novel reassortant H3N2 SIV strain, designated A/Swine/Jiangsu/YZ07/2024, was isolated from pigs exhibiting clinical symptoms in Northern Jiangsu, China during epidemiological survey. Genetic analysis revealed that the virus is a complex reassortant, with the internal genes (M, NP, PB1, PB2, PA) originated from the 2009 pandemic H1N1 lineage, the NS gene exhibiting a North American triple reassortant origin (human-avian-swine origin), and the HA and NA genes belonging to the human-like lineage. Although neither the rescued virus nor its parental strain could replicate effectively in chicken embryos and chicken cells, both demonstrated efficient replication in mammalian cells, reflected by the much higher polymerase activity in mammalian versus chicken cells. The key residues of HA protein (190D, 225D and 228S) collectively enhanced the binding preference for human-type α-2,6-linked sialic acid receptors, which was confirmed by receptor binding assays. Furthermore, mouse infection experiments using the rescued H3N2 demonstrated efficient viral replication in nasal turbinates and lung tissues, accompanied by significant pulmonary pathological damage. These findings indicate that the YZ07 strain, through the vast reassortment and accumulation of adaptive mutations, has acquired potential zoonotic risk, underscoring the importance of surveillance of swine influenza viruses.

Source: 


Link: https://www.sciencedirect.com/science/article/abs/pii/S0378113526000684?via%3Dihub

____

Thursday, January 15, 2026

Genetic Characterization and Evolutionary #Insights of Novel #H1N1 Swine #Influenza Viruses Identified from #Pigs in #Shandong Province, #China

 


Abstract

Influenza A viruses exhibit broad host tropism, infecting multiple species including humans, avian species, and swine. Swine influenza virus (SIV), while primarily circulating in porcine populations, demonstrates zoonotic potential with sporadic human infections. In this investigation, we identified two H1N1 subtype swine influenza A virus strains designated A/swine/China/SD6591/2019(H1N1) (abbreviated SD6591) and A/swine/China/SD6592/2019(H1N1) (abbreviated SD6592) in Shandong Province, China. The GenBank accession numbers of the SD6591 viral gene segments are PV464931-PV464938, and the GenBank accession numbers corresponding to each of the eight SD6592 viral gene segments are PV464939-PV464946. Phylogenetic and recombination analyses suggest potential evolutionary differences between the isolates. SD6591 displayed a unique triple-reassortant genotype: comparative nucleotide homology assessments demonstrated that the PB2, PB1, NP, NA, HA, and NEP genes shared the highest similarity with classical swine-origin H1N1 viruses. In contrast, SD6592 maintained genomic conservation with previously characterized H1N1 swine strains, although neither of these two isolates exhibited significant intrasegmental recombination events. Through comprehensive sequence analysis of these H1N1 SIVs, this study provides preliminary insights into their evolutionary history and underscores the persistent risk of cross-species transmission at the human–swine interface. These findings establish an essential foundation for enhancing national SIV surveillance programs and informing evidence-based prevention strategies against emerging influenza threats.

Source: 


Link: https://www.mdpi.com/1999-4915/18/1/117

____

Monday, December 22, 2025

Digest: #Reassortment-based #evolution of #H1N1 subtype Swine #Influenza Virus in #China

 


Abstract

In a new study, Zhao et al. (2025) obtain 959 whole genome sequences of H1N1 subtype swine influenza virus (SIV) isolated from China. Their analysis of the sequences, isolated between 1977 and 2020, reveals how H1N1 lineages have co-evolved and contributed to instances of zoonotic transmission within the region. This study’s findings characterize the long-term evolutionary effects of frequent viral reassortment in SIV and highlight its potential to drive future pandemics.

Source: 


Link: https://academic.oup.com/evolut/advance-article/doi/10.1093/evolut/qpaf262/8400336

____

#Influenza at the #human - #animal #interface - Summary and #risk #assessment, from 6 November to 19 December 2025 (#WHO, edited)

 


Influenza at the human-animal interface 

Summary and risk assessment, from 6 November to 19 December 2025 {1}


-- New human cases {1,2}: 

- From 6 November to 19 December 2025, based on reporting date, the detection of influenza A(H5N1) in one human, A(H5N5) in one human, A(H9N2) in seven humans, and an influenza A(H1N1) variant virus in one human were reported officially. 

- In addition, one human case of infection with an influenza A(H1N2) variant virus was detected. 


-- Circulation of influenza viruses with zoonotic potential in animals

- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

- The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

- Additionally, low pathogenicity avian influenza viruses as well as swine influenza viruses continue to circulate in animal populations. 


-- Risk assessment {5}: 

- Sustained human to human transmission has not been reported associated with the above-mentioned human infection events. 

- Based on information available at the time of this risk assessment update, the overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and remains low

- The occurrence of sustained human-to-human transmission of these viruses is currently considered unlikely

- Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  


-- IHR compliance {6}: 

- This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

- Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.  


Avian influenza viruses in humans 

-- Current situation:  

- Since the last risk assessment of 5 November 2025, one laboratory-confirmed human case of A(H5N1) infection was detected in Cambodia, and one laboratory-confirmed human case of A(H5N5) virus infection was detected in the United States of America


A(H5N1), Cambodia 

- On 16 November 2025, Cambodia notified WHO of a confirmed human infection with avian influenza A(H5N1) in a 22-year-old male from Phnom Penh

- The case developed symptoms on 10 November 2025, sought medical care at a clinic, and was diagnosed with pneumonia. 

- He was subsequently admitted to the national hospital in Phnom Penh on 13 November. 

- Samples were collected on the same day and tested positive for avian influenza A(H5N1) on 15 November. 

- His condition deteriorated rapidly, and he died the same day.   

- Investigations conducted in the case's hometown in Kampong Cham Province, which he visited between 4 and 6 November, revealed that the case had apparently healthy domestic birds (chickens and ducks) in his house. 

- However, sick and dead poultry had been reported in the village since 15 October

- Samples collected from two ducks and one chicken in the village tested positive for influenza A(H5N1). 

- Enhanced public health surveillance was implemented. 

- Among the case’s contacts, one was symptomatic, and all contacts tested negative for influenza A(H5N1).  

- Eighteen human infections with A(H5N1) viruses have been confirmed in Cambodia in 2025 and nine of these have been fatal

- All these cases in 2025 had exposure to domestic birds or their environments. 

- In some cases, domestic birds were reported to be sick or dead. 

- Where the information is available, the genetic sequence data from the viruses from the human cases closely matches that from recent local animal viruses and are identified as clade 2.3.2.1e viruses

- From the information available thus far on these recent human cases, there is no indication of human-tohuman transmission of the A(H5N1) viruses.  


A(H5N5), United States of America 

- On 15 November 2025, the United States of America (US) notified WHO of a confirmed human infection with influenza A(H5). 

- The patient was an adult with underlying medical conditions residing in Washington State

- The patient developed symptoms including fever during the week ending 25 October 2025. 

- During the week ending 8 November 2025, the patient was hospitalized with a serious illness and subsequently died on 21 November.  

- Respiratory specimens collected at the healthcare facility tested positive for influenza A virus by reverse-transcription-polymerase chain reaction (RT-PCR) and were presumptive positive for influenza A(H5) at the laboratory at the University of Washington. 

- The specimens were sent to the Washington State Public Health Laboratory, where influenza A(H5) was confirmed with the US Centers for Disease Control and Prevention (CDC) influenza A(H5) assay. 

- The sample was received at the CDC on 19 November. Sequencing conducted at the University of Washington and at the CDC indicated this was an influenza A(H5N5) virus belonging to the H5 haemagglutinin (HA) clade 2.3.4.4b.  

- Public health investigation revealed that the patient kept backyard poultry and domestic birds. 

- Additional epidemiological investigations were under way at the time of notification and included active monitoring of anyone who was in close contact with the patient.{7,8} 

- This is the first human case of this subtype reported globally. 

- Human infections with A(H5N1), A(H5N2), A(H5N6) and A(H5N8) have been reported previously. 

- A(H5N5) virus infections in animals have been detected and reported. 

- HPAI A(H5) clade 2.3.4.4b A(H5N5) viruses have been detected in North America in wild birds and wild mammals since at least 2023.{9} 

- According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe

- Infections in non-human mammals are also reported, including in marine and land mammals.{10} 

- A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{11}


-- Risk Assessment for avian influenza A(H5) viruses:  

1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?  

- Most human infections so far have been reported in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

- As long as the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but remain unusual. 

- The impact for public health if additional sporadic cases are detected is minimal

- The current overall global public health risk of additional sporadic human cases is low


2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H5) viruses related to the events above?  

- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5) viruses. 

- There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

- In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  

- Current evidence suggests that influenza A(H5) viruses related to these events did not acquire the ability to efficiently transmit between people, therefore sustained human-to-human transmission is thus currently considered unlikely.  


3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?  

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


A(H9N2), China  

- Since the last risk assessment of 5 November 2025, China notified WHO of four cases of infection with influenza A(H9N2) on 6 November 2025 and three cases on 12 December 2025. 

- All but two cases were in children

- Cases were detected in Guangdong (one), Guangxi (three), Henan (one) and Hubei (two) provinces. 

- The cases had onsets of symptoms in September, October and November 2025. 

- Four cases had reported exposure to backyard poultry, two had exposure to live poultry markets and the source of exposure for one case was under investigation at the time of reporting. 

- All cases had mild illness and recovered, except one in an elderly person with underlying conditions who was hospitalized at the time of reporting with severe pneumonia. 

- No further cases were detected among contacts of these cases. 

- A(H9) viruses were detected in environmental samples collected during the investigations around some of the cases. 


-- Risk Assessment for avian influenza A(H9N2):   

- 1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?   

- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. 

- Most human infections of A(H9N2) to date have resulted in mild clinical illness

- Since the virus is endemic in poultry in multiple countries in Africa and Asia, further human cases associated with exposure to infected poultry are expected but remain unusual. 

- The impact to public health if additional sporadic cases are detected is minimal

- The overall global public health risk of additional sporadic human cases is low.  


2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses related to this event?   

- At the present time, no sustained human-to-human transmission has been identified associated with the recently reported human infections with A(H9N2) viruses. 

- Current evidence suggests that A(H9N2) viruses from these cases did not acquire the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.   


3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?   

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.   


Swine influenza viruses in humans 

Influenza A(H1N1)v, China 

- Since the last risk assessment of 5 November 2025, the detection of a Eurasian avian-like swine influenza A(H1N1)v virus in a human was reported from China on 12 December 2025. 

- A 60-year-old male from Yunnan province had onset of mild illness on 2 November 2025, was hospitalized on 6 November and discharged on 10 November. 

- He had reported exposure to backyard pigs


Influenza A(H1N2)v, USA 

- A human case of infection with an influenza A(H1N2)v virus was detected in the state of Vermont in an adult who had an onset of symptoms in early October. 

- The individual was briefly hospitalized and has recovered. 

- The investigation conducted by state public health officials was unable to determine the likely source of exposure or if close contacts developed symptoms. 

- According to the report, no human-to-human transmission was identified associated with this case.{12}  


-- Risk Assessment:  

1. What is the public health risk of additional human cases of infection with swine influenza viruses?  

- Swine influenza viruses circulate in swine populations in many regions of the world. 

- Depending on geographic location, the genetic characteristics of these viruses differ. 

- Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. 

- Human infection tends to result in mild clinical illness in most cases. 

- Since these viruses continue to be detected in swine populations, further human cases are expected. 

- The impact to public health if additional sporadic cases are detected is minimal

- The overall risk of additional sporadic human cases is low.  


2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?   

- No sustained human-to-human transmission was identified associated with the events described above. 

- Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely. 


3. What is the likelihood of international spread of swine influenza viruses by travelers?   

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further community level spread is considered unlikely as current evidence suggests that these viruses have not acquired the ability to transmit easily among humans. 


Overall risk management recommendations

-- Surveillance and investigations

Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses

As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

Countries should increase avian influenza surveillance in: 

- domestic and wild birds,

- enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, 

- include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; 

- monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, 

- share genetic sequences of avian influenza viruses in publicly available databases, 

- implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, 

- employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{13} 

- More guidance can be found from WOAH and FAO

- When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. 

- Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: 

> enhanced surveillance in local influenza-like illness (ILI)/SARI systems, 

> active screening in hospitals and of groups that may be at higher occupational risk of exposure, and 

> inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

Vigilance for the emergence of novel influenza viruses with pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance


-- Notifying WHO 

All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{14} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{15} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{16}. Evidence of illness is not required for this report. Evidence of illness is not required for this report. 

WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions


-- Virus sharing and risk assessment 

It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{17} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


-- Risk reduction 

Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


-- Trade and travellers 

WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

-- WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

-- WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

-- WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

-- WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

-- Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

-- Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

-- World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

-- Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

-- OFFLU http://www.offlu.org/ 

___

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).   

{7} World Health Organization (5 December 2025). Disease Outbreak News; Avian Influenza A(H5N5)- United States of America. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2025DON590

{8} US CDC FluView. Weekly US Influenza Surveillance Report: Key Updates for Week 46, ending November 15, 2025. Available at https://www.cdc.gov/fluview/surveillance/2025-week-46.html

{9} Erdelyan CNG, Kandeil A, Signore AV, et al. Multiple transatlantic incursions of highly pathogenic avian influenza clade 2.3.4.4b A(H5N5) virus into North America and spillover to mammals. Cell Rep. 2024 Jul 23;43(7):114479. doi:10.1016/j.celrep.2024.114479. Epub 2024 Jul 13. PMID:39003741; PMCID:PMC11305400. 

{10}  World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{11} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{12} US CDC FluView. Weekly US Influenza Surveillance Report: Key Updates for Week 46, ending November 15, 2025. Available at https://www.cdc.gov/fluview/surveillance/2025-week-46.html

{13} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/

{14} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005). 

{15} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518

{16} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850

{17} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/259402

___

Source: 


Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--19-december-2025

____

Friday, December 12, 2025

#Vaccine-induced #antigenic #drift of a #human-origin #H3N2 #Influenza A virus in swine alters glycan binding and sialic acid avidity

 


Abstract

Interspecies transmission of human influenza A viruses (FLUAV) to swine occurs frequently, yet the molecular factors driving adaptation remain poorly understood. Here we investigated how vaccine-induced immunity shapes the evolution of a human-origin H3N2 virus in pigs using an in vivo sustained transmission model. Pigs (seeders) were vaccinated with a commercial inactivated swine vaccine and then infected with an antigenically distinct FLUAV containing human-origin HA/NA. Contact pigs were introduced two days later. After 3 days, seeder pigs were removed, and new contacts introduced. This was repeated for a total of 4 contacts. Sequencing of nasal swab samples showed the emergence of mutations clustered near the HA receptor binding site, enabling immune escape and abolishing binding to N-glycolylneuraminic acid. Mutant viruses recognized α2,6-sialosides with 3 N-acetyllactosamine repeats, which are rare in swine lungs, while the parental virus bound structures with a minimum of 2 repeats. Adaptative HA mutations enhanced avidity for α2,6-linked sialic acid, likely compensating for the low abundance of extended glycans. Notably, residues outside the canonical HA binding pocket contribute to glycan binding, suggesting a trade-off between receptor breadth and avidity. These findings show that non-neutralizing immunity promotes viral adaptation by fine-tuning receptor engagement and immune evasion.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2025.12.10.693614v1

____

Friday, November 21, 2025

#USA, Novel #Influenza A Virus #Infections: 1 case of #H5N5 and 1 case of #H1N2v detected (CDC, Nov. 21 '25)

 


{Excerpt}

Novel Influenza A Virus Infections

Two confirmed human infections with novel influenza A viruses were reported to CDC this week

One infection with an influenza A(H5N5) virus was reported by the Washington State Department of Health and one infection with an influenza A(H1N2) variant (A(H1N2)v) virus was reported by the Vermont Department of Health.

One infection with an influenza A(H5N5) virus was reported by the Washington State Department of Public Health

-- The case occurred in an individual aged ≥18 years

-- This individual developed symptoms during the week ending October 25, 2025 (Week 43) and was hospitalized with their illness during the week ending November 8, 2025 (Week 45). 

-- Respiratory specimens collected at the healthcare facility tested positive for influenza A and were presumptive positive for influenza A(H5) at the University of Washington. 

-- The specimens were sent to the Washington State Public Health Laboratory where influenza A(H5) was confirmed using the CDC influenza A(H5) assay. 

-- Sequencing conducted at the University of Washington and at the CDC indicated this was an influenza A(H5N5) virus.

-- The investigation by public health officials identified that the patient kept backyard poultry that had exposure to wild birds

-- The patient remains hospitalized

-- This is the twelfth confirmed influenza A(H5) case in Washington overall. 

-- Prior confirmed cases in Washington were associated with commercial poultry exposure. 

-- This is the 71st confirmed human case of A(H5) in the United States since early 2024 and the first human case reported in the United States since February 2025.

One infection with an influenza A(H1N2)v virus was reported by the Vermont Department of Health in an individual aged ≥18 years

-- The individual developed symptoms and sought healthcare during the week ending October 4, 2025 (Week 40), was hospitalized but discharged on the same day, and has recovered from their illness. 

-- The investigation conducted by state public health officials was unable to determine whether the individual had exposure to swine or other animals, or whether the patient's close contacts exhibited any illness. 

-- No human-to-human transmission has been identified associated with this case.

-- When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

(...)

Source: 


Link: https://www.cdc.gov/fluview/surveillance/2025-week-46.html

____

Friday, October 31, 2025

#Genetic and #antigenic characteristics of #zoonotic #influenza A viruses and development of candidate #vaccine viruses for pandemic preparedness (#WHO, Oct. 31 '25)

 


September 2025 

The development of influenza candidate vaccine viruses (CVVs), coordinated by WHO, remains an essential component of the overall global strategy for influenza pandemic preparedness. Selection and development of CVVs are the first steps towards timely vaccine production and do not imply a recommendation for initiating manufacture. National authorities may consider the use of one or more of these CVVs for pilot lot vaccine production, clinical trials and other pandemic preparedness purposes based on their assessment of public health risk and need. 

Zoonotic influenza viruses continue to be identified and evolve both antigenically and genetically, leading to the need for additional CVVs for pandemic preparedness purposes. 

Changes in the antigenic and genetic characteristics of these viruses relative to existing CVVs and their potential risks to public health justify the need to develop new CVVs. This document summarizes the antigenic and genetic characteristics of recent zoonotic influenza viruses and related viruses circulating in animals{1} that are relevant to CVV updates. 

Institutions interested in receiving these CVVs should contact WHO at gisrs-whohq@who.int or the institutions listed in announcements published on the WHO website.{2} 


Influenza A(H5) 

Since their emergence in 1997, high pathogenicity avian influenza (HPAI) A(H5) viruses of the A/goose/Guangdong/1/96 haemagglutinin (HA) lineage have become enzootic in many countries, have infected wild birds and continue to cause outbreaks in poultry and sporadic human and other mammalian infections across a wide geographic area. 

A(H5) HA gene segments have paired with a variety of neuraminidase (NA) subtypes (N1, N2, N3, N4, N5, N6, N8 or N9). These viruses have diversified genetically and antigenically, leading to the need for multiple CVVs. This summary provides updates on the characterization of A/goose/Guangdong/1/96-lineage A(H5) viruses and the status of the development of influenza A(H5) CVVs. 


Influenza A(H5) activity from 25 February  to 22 September 2025 

Since 2003, 17 A(H5), 7 A(H5N8), 93 A(H5N6) and 979 A(H5N1) human infections or detections have been reported. 

Since 25 February 2025, 24 human infections with A/goose/Guangdong/1/96-lineage viruses have been reported to WHO. 

A/goose/Guangdong/1/96-lineage A(H5) viruses have been detected in both domestic and wild birds with spillover to mammals in many countries (...). 


Genetic and antigenic characteristics  of influenza A(H5) viruses 

Twenty-four new human infections or detections with A/goose/Guangdong/1/96-lineage viruses were reported. 

Most infected individuals had recent exposure to birds. The human cases included 4 A(H5N1) clade 2.3.2.1a infections, 2 in Bangladesh and 2 fatal infections in India

Bangladesh reported additional single A(H5) and A(H5N1) cases where clade designations could not be determined due to lack of sequence data. 

The HA of the 2.3.2.1a viruses from Bangladesh and India had up to 1 and 7 amino acid substitutions relative to the A/Victoria/149/2024 CVV, respectively. 

Antigenic analyses of the viruses from the human cases are pending, but a genetically related virus from poultry in Bangladesh reacted well to post-infection ferret antisera raised against the A/Victoria/149/2024 CVV. 

Two human cases of A(H5N1) clade 2.3.4.4b virus infection were detected; 1 in China in an individual with recent travel history to Viet Nam, and 1 fatal case in Mexico

The A(H5N1) clade 2.3.4.4b virus from China had an HA with 4 amino acid substitutions relative to the A/Jiangsu/ NJ210/2023 CVV. The virus from the human case in Mexico had an HA with 3 amino acid substitutions 

(...)

relative to the A/Astrakhan/3212/2020 and A/Ezo red fox/Hokkaido/1/2022 CVVs, however, 1 of the substitutions added a putative glycosylation site in antigenic site B. Antigenic analyses are pending. 

Cambodia reported fifteen human cases of A(H5N1) of which 6 were fatal. Viruses from twelve cases were confirmed as belonging to A(H5N1) clade 2.3.2.1e; clade designations could not be determined for the other 3 due to lack of sequence data. 

One human infection with an A(H5N1) clade 2.3.2.1e virus was identified in Viet Nam

The HAs of the human viruses from Cambodia and Viet Nam had, at most, 4 amino acid differences relative to the A/Cambodia/SVH240441/2024 CVV. Ferret antisera raised against A/Cambodia/SVH240441/2024 and the A/Cambodia/SVH240441/2024 CVV reacted well with virus isolated from the human case detected in Viet Nam but less well with a virus from a Cambodian human case. 

Ferret antisera raised against A/duck/Vietnam/NCVD-1584/2012 and the clade 2.3.2.1f A/chicken/ Ghana/20/2015 CVV reacted well with the Cambodian virus. Antigenic characterisation of other viruses isolated from human cases in Cambodia is pending.

A(H5) viruses from birds and non-human mammals belonged to the following clades Clade 2.3.2.1a viruses were detected in poultry and wild birds in Bangladesh and in poultry, wild birds, captive tigers and leopards, and domestic cats in India. 

Circulation of viruses with clade 2.3.2.1a HAs in these countries has continued despite the introduction of clade 2.3.4.4b viruses. 

The HA of viruses detected in poultry in Bangladesh and India had up to 1 and 5 amino acid substitutions relative to the A/Victoria/149/2024 CVV, respectively. No antigenic data are available for these viruses. Viruses collected in the previous reporting period had HAs genetically similar to either the A/Victoria/149/2024 or A/duck/Bangladesh/17D1012/2018 CVVs and reacted well to post-infection ferret antisera raised against at least 1 of the available clade 2.3.2.1a CVVs. 

Clade 2.3.4.4b viruses were detected in birds in Africa, North and South America, Antarctica, Asia and Europe. A(H5N1) viruses circulated in birds in most regions; A(H5N6) viruses were detected in poultry in China; A(H5N5) viruses were detected in Europe and North America; A(H5N8) viruses continued to circulate in Egypt; and A(H5N2) viruses were detected in wild birds in Japan

Infections in wild and captive mammals have been reported in many countries and the outbreak in dairy cattle continued in the USA

The HAs of A(H5N1) clade 2.3.4.4b viruses detected in birds in Argentina, Bolivia and Brazil were similar to viruses circulating in the region during previous reporting periods with up to 6 amino acid substitutions relative to the A/American wigeon/South Carolina/22-000345-001/2021 CVV. No antigenic data were available. 

Although some heterogeneity was observed, A(H5N1) viruses from birds and mammals in Bangladesh, Japan and the USA and multiple countries in Africa and Europe generally reacted well with post-infection ferret antisera raised against at least 1 of the available clade 2.3.4.4b CVVs; a virus from Crozet Islands and an increasing number of viruses from Egypt reacted less well. 

The A(H5N6) and A(H5N1) viruses identified in China had 2 to 14 HA amino acid substitutions relative to clade 2.3.4.4b CVVs and most reacted well with post-infection ferret antisera raised against CVV-like viruses. 

The HAs of A(H5N5) viruses detected in Europe and North America were genetically related to viruses detected in previous reporting periods and reacted well to ferret antisera raised against at least 1 of the available clade 2.3.4.4b CVVs. 

Clade 2.3.2.1e viruses were detected in poultry in Cambodia, Lao People’s Democratic Republic (Lao PDR) and Viet Nam. The HAs of these viruses were similar to viruses detected in previous periods in the region, with 1 to 9 amino acid substitutions relative to the recommended clade 2.3.2.1e A/Cambodia/ SVH240441/2024 CVV. Antigenic analyses are pending.

Clade 2.3.2.1g viruses were detected in poultry in multiple islands of the Republic of Indonesia. These viruses had HAs genetically similar to those of viruses circulating in the previous reporting period (...). Currently, there is no CVV proposed for this clade. These viruses accumulated many amino acid substitutions when compared to the sequences of CVVs of closely related clades. 

Antigenic analyses showed these viruses reacted poorly with post-infection ferret antisera raised against the clade 2.3.2.1e A/duck/Vietnam/ NCVD-1584/2012 and the clade 2.3.2.1a A/duck/Bangladesh/17D1012/2018 CVVs. 

Some of the recent Indonesian viruses reacted well to post-infection ferret antiserum raised against the clade 2.3.2.1f A/chicken/ Ghana/20/2015 CVV. 


Influenza A(H5) candidate vaccine viruses 

Based on current genetic, antigenic and epidemiologic data, no new CVVs are proposed. The available and pending A(H5) CVVs are listed in Table 2. 


Influenza A(H9N2) 

Influenza A(H9N2) viruses are enzootic in poultry in many parts of Africa, Asia and the Middle East, with the majority of viruses belonging to either the B or G HA lineage.{3} 

Since the late 1990s, when the first human infection was identified, sporadic detections of A(H9N2) viruses in humans and pigs have been reported, with associated mild disease in most human cases and no evidence for sustained human-to-human transmission


Influenza A(H9N2) activity from 25 February  to 22 September 2025 

Twenty-four human infections with A(H9N2) viruses have been identified in China, 4 with disease onset dates in the previous reporting period. 

A(H9N2) viruses were detected in poultry in multiple countries in Africa, Asia and the Middle East and in an illegally imported poultry product in Japan. 


Genetic and antigenic characteristics  of influenza A(H9N2) viruses 

The HAs of the 15 sequenced human viruses belonged to clade B4.7. Fourteen of these viruses belonged to clade B4.7.2 and had up to 25 amino acid substitutions relative to the A/Anhui-Tianjiaan/11086/2022 CVV. 

The other human virus had a clade B4.7.4 HA with 14 amino acid substitutions relative to the A/Anhui-Lujiang/39/2018 CVV. 

The majority of human viruses tested antigenically reacted well to post-infection ferret antisera raised against the A/Anhui-Tianjiaan/11086/2022 or the A/Anhui-Lujiang/39/2018 CVV. 

(...)

A(H9N2) viruses from birds belonged  to the following clades: A Clade B4.6 virus was detected in an imported poultry product in Japan. The HA of this virus was genetically similar to viruses previously reported in China, Lao PDR and Singapore. There is currently no CVV for clade B4.6, but the virus reacted well to post-infection ferret antisera raised against both the clade G5.5 A/Oman/2747/2019 and clade B-like A/chicken/Hong Kong/G9/97 CVVs. 

Clade B4.7 viruses were detected in poultry in Cambodia and Viet Nam. The HAs of these viruses continued to diversify genetically and accumulated up to 21 amino acid substitutions relative to the A/Anhui-Tianjiaan/11086/2022 CVV. No antigenic data were available from these viruses. 

Clade G5.5 viruses were detected in poultry in Israel, Nigeria and Togo. Moreover, viruses belonging to clade G5.5 were identified in poultry in Mauritania and Senegal, although from samples collected in the previous reporting period. The HAs of the viruses from Israel had accumulated 8 amino acid substitutions relative to the A/Oman/2747/2019 CVV. The HAs of viruses from Nigeria, Mauritania, Senegal and Togo were genetically related to viruses circulating in West Africa in the previous period and had up to 12 amino acid substitutions relative to the A/Oman/2747/2019 CVV. 

Ferret antiserum raised against the A/Oman/2747/2019 CVV reacted well with a virus from Togo. No antigenic data were available for the other G5.5 viruses. 

Clade G5.6 viruses were detected in poultry in Egypt. These viruses had up to 35 amino acid substitutions relative to the A/Oman/2747/2019 CVV. Ferret antisera raised against either the A/Hong Kong/G9/97 or A/Oman/2747/2019 CVVs, however, reacted well with the majority of the viruses tested. 

Clade G5.7 viruses were detected in poultry in Bangladesh and India, although from samples collected during the previous reporting period. The HAs of viruses identified in India were genetically related to those circulating during previous reporting periods and had accumulated up to 28 amino acid substitutions relative to the A/Bangladesh/0994/2011 CVV with 8 amino acid substitutions occurring in putative antigenic sites. 

Ferret antiserum raised against the A/Bangladesh/0994/2011 CVV reacted well with the majority of Bangladesh viruses tested, however, some viruses with mutations in putative antigenic sites reacted less well. 

Clade Y8 viruses were detected in poultry in France and Madagascar, and in wild birds in Europe and North America. The HA sequences of viruses detected in Madagascar were similar to previously reported viruses in the country. The HA sequence of the virus from France was genetically similar to viruses previously reported in Europe. No antigenic data were available for these viruses and there is currently no CVV for this clade. 


Influenza A(H9N2) candidate vaccine viruses 

Based on the available antigenic, genetic and epidemiologic data, no new CVVs are proposed. The available and pending A(H9N2) CVVs are listed in Table 3. 


Influenza A(H10) 

A(H10) viruses are frequently detected in poultry in many regions of the world and are considered endemic in poultry in China, with rare human infections reported. 

Prior to this reporting period, 4 A(H10N3), 1 A(H10N5) and 3 A(H10N8) human infections were detected in China and A(H10N7) viruses were detected in individuals with conjunctivitis or mild upper respiratory tract symptoms in Australia (n=2) and Egypt (n=2). 


Influenza A(H10) activity from 25 February  to 22 September 2025 

Two human A(H10N3) virus infections were identified in China

(...)


Antigenic and genetic characteristics  of influenza A(H10N3) viruses 

One of the human A(H10N3) viruses was sequenced and had an HA that was genetically similar to human A(H10N3) viruses from 2024, maintaining avian virus signatures at key receptor binding sites. As with previous viruses, the recent A(H10N3) virus had some gene segments derived from A(H9N2) viruses. No virus was recovered from the clinical material. 

A(H10N3), A(H10N4) and an A(H10N8) virus were detected in ducks and chickens in Fujian and Jiangxi Provinces of China, some with collection dates during the previous reporting period. The HAs of these viruses formed subtype-specific phylogenetic clades with those of the A(H10N3) viruses being genetically similar to the human A(H10N3) viruses. 

A(H10N7) viruses, genetically similar to those detected in previous periods, were detected in ducks in Cambodia


Influenza A(H10N3) candidate vaccine viruses 

Based on the available genetic and epidemiologic data, no new CVVs are proposed. The pending A(H10N3) CVV is listed in Table 4. 


Influenza A(H1)v{4} 

Influenza A(H1) viruses are enzootic in swine populations in most regions of the world. The genetic and antigenic characteristics of the viruses circulating in different regions are diverse. Viruses isolated from human infections with swine influenza A(H1) viruses are designated as A(H1) variant ((H1)v) viruses and have been previously detected in the Americas, Asia and Europe. 


Influenza A(H1)v activity from 25 February  to 22 September 2025 

One case of infection with an A(H1N1)v virus was detected in Germany. Multiple clades of A(H1) viruses were detected in swine populations globally (...). 

(...)

Antigenic and genetic characteristics  of influenza A(H1N1)v viruses 

The A(H1N1)v virus case from Germany was sequenced and had an HA belonging to clade 1C.2.2 similar to other 1C.2.2 viruses detected in swine in the region. The HA had 27 amino acid substitutions compared to the clade 1C.2.2 CVV, A/Hessen/47/2020. No antigenic data were available. 


Influenza A(H1)v candidate vaccine viruses 

Based on the available antigenic, genetic and epidemiologic data, no new A(H1)v CVVs are proposed. The available and pending A(H1)v CVVs are listed in Table 6. 


Influenza A(H3N2)v 

Influenza A(H3N2) viruses with diverse genetic and antigenic characteristics are enzootic in swine populations in most regions of the world. Human infections with influenza A(H3N2)v viruses originating from swine have been previously documented in the Americas, Asia, Australia and Europe. 


Influenza A(H3N2)v activity from 25 February  to 22 September 2025 

No cases of infection with A(H3N2)v viruses were detected in this reporting period. A(H3N2) viruses were detected in swine in Canada, France, Italy, Portugal, Russian Federation and the USA (Table 7). 

(...)

Influenza A(H3N2)v candidate vaccine viruses 

Based on the available antigenic, genetic and epidemiologic data, no new CVVs are proposed. The available A(H3N2)v CVVs are listed in Table 8

(...)


Acknowledgements 

Acknowledgement goes to the WHO Global Influenza Surveillance and Response System (GISRS) which provides the mechanism for detection and monitoring of zoonotic influenza viruses. We thank the National Influenza Centres of GISRS who contributed information, clinical specimens and viruses, and associated data; WHO collaborating centres of GISRS for their in-depth characterisation and analysis of viruses and preparation of CVVs; WHO Essential Regulatory Laboratories of GISRS; and WHO H5 Reference Laboratories for their complementary analyses and preparation of CVVs. We acknowledge the WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) laboratories for their in-depth characterization and comprehensive analysis of viruses and other national public and veterinary health institutions for contributing information and viruses. We also acknowledge the GISAID Global Data Science Initiative for the EpiFluTM database, and other sequence databases which were used to share gene sequences and associated information. 


{1} For information relevant to other notifiable influenza virus infections in animals refer to https://wahis.woah.org/#/home 

{2} See https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses  

{3} See https://wwwnc.cdc.gov/eid/article/30/8/23-1176_article 

{4} Standardization of terminology for the influenza virus variants infecting humans: Update (https://cdn.who.int/media/docs/default-source/influenza/global-influenza-surveillance-and-response-system/nomenclature/standardization_of_terminology_influenza_virus_variants_update.pdf?sfvrsn=d201f1d5_6).


Source: World Health Organization, Weekly Epidemiological Record (WER), https://iris.who.int/server/api/core/bitstreams/af989289-7535-4a61-89b9-5db72aa5e829/content

____


Tuesday, October 14, 2025

#Influenza at the #human - #animal #interface - Summary and #risk #assessment, from 26 August to 29 September 2025 (#WHO, edited)

 


New human cases {1,2}: 

-- From 26 August to 29 September 2025, based on reporting date, the detection of influenza A(H5) in one human, influenza A(H5N1) in one human, influenza A(H9N2) in eight humans and an influenza A(H1N1) variant ((H1N1)v) virus in one human were reported officially.  


Circulation of influenza viruses with zoonotic potential in animals

-- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

-- The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 


Risk assessment {5}: 

-- Sustained human to human transmission has not been reported from these events. 

-- Based on information available at the time of this risk assessment update, the overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and remains low

-- The occurrence of sustained human-to-human transmission of these viruses is currently considered unlikely

-- Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  


Risk management

-- Candidate vaccine viruses (CVVs) for zoonotic influenza viruses for pandemic preparedness purposes were reviewed and updated at the September 2025 WHO consultation on influenza vaccine composition for use in the southern hemisphere 2026 influenza season. 

-- A detailed summary of zoonotic influenza viruses characterized since February 2025 is published here and updated CVVs lists are published here. 


IHR compliance

-- All human infections caused by a new influenza subtype are required to be reported under the International Health Regulations (IHR).{6} 

-- This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

-- Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.


Avian influenza viruses in humans 

Current situation:  

-- Since the last risk assessment of 25 August 2025, one laboratory-confirmed human case of A(H5) infection was detected in Bangladesh, and one laboratory-confirmed human case of A(H5N1) virus infection was detected in Cambodia


A(H5), Bangladesh 

-- On 19 August 2025, Bangladesh notified WHO of one laboratory-confirmed human infection with avian influenza A(H5) virus in a boy in Sylhet Division

-- The case developed fever and cough on 27 July and was admitted to hospital on 1 August. 

-- Oropharyngeal and nasopharyngeal swabs collected on 4 August and tested at the Virology Laboratory of the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and the Institute of Epidemiology, Disease Control & Research (IEDCR) tested positive for influenza A(H5) virus by reverse transcription-polymerase chain reaction (RT-PCR) on 14 August.

-- Subtyping for the N-type was pending at the time of notification. 

-- The case was detected through the Hospital-Based Influenza Surveillance (HBIS) platform. The case was discharged on 7 August.  

-- A seven-member multidisciplinary team, comprising physicians, epidemiologists, an anthropologist, and a technologist, was deployed on 15 August to conduct an investigation. 

-- The child had no history of travel and no reported exposure to backyard poultry, however the family purchased chickens from a local market in the days preceding the child’s illness. 

-- All samples collected from contacts tested negative for influenza A(H5) virus. 

-- Samples collected poultry at two markets that were frequently visited by the family of the case tested positive for influenza A(H5) virus.  

-- This is the 12th human case of avian influenza A(H5) reported to WHO from Bangladesh and the fourth in 2025. Where the genetic sequence data is available, the viruses from the human cases thus far are identified as clade 2.3.2.1a viruses


A(H5N1), Cambodia 

-- On 9 September 2025, Cambodia notified WHO of a laboratory-confirmed human infection with avian influenza A(H5N1) in a girl from Takeo Province

-- The case, with no known underlying medical conditions, had an onset of fever, cough and dyspnea on 1 September and was admitted to hospital on 5 September. Nasopharyngeal and oropharyngeal swabs collected on 7 September tested positive for avian influenza A(H5N1) at the National Institute of Public Health (NIPH) RT-PCR. 

-- Laboratory results were confirmed by the Institut Pasteur du Cambodge, National Influenza Center (NIC) on 8 September. 

-- Treatment with oseltamivir was initiated on 7 September.   

-- As part of the response, active case finding identified 10 close contacts and two villagers presenting with influenza-like illness (ILI). 

-- All nasopharyngeal and oropharyngeal samples collected from close contacts, symptomatic villagers and health workers tested negative for influenza A(H5N1) virus. 

-- A week before symptom onset, approximately 10 to 20 sick or dead chickens were observed at the case’s residence and at a neighbouring house. 

-- The case prepared and cooked sick/dead chickens. Samples collected from chickens and a duck in the village during the investigation tested positive for A(H5N1).

-- Sixteen human infections with A(H5N1) viruses have been confirmed in Cambodia in 2025 and eight of these have been fatal. All these cases in 2025 had exposure to domestic birds or their environments. In some cases, the domestic birds were reported to be sick or dead. Where the information is available, the genetic sequence data from the viruses from the human cases closely matches that from recent local animal viruses and are identified as clade 2.3.2.1e viruses

-- From the information available thus far on these recent human cases, there is no indication of human-to-human transmission of the A(H5N1) viruses.  

-- According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe. 

-- Infections in non-human mammals are also reported, including in marine and land mammals.{7} 

-- A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{8}


Risk Assessment for avian influenza A(H5) viruses:  

1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?  

-- Most human infections so far have been in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

-- As long as the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but remain unusual. 

-- The impact for public health if additional sporadic cases are detected is minimal

-- The current overall global public health risk of additional sporadic human cases is low


2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H5) viruses related to the events above?  

-- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5) viruses. 

-- There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

-- In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  

-- Current evidence suggests that influenza A(H5) viruses related to these events did not acquire the ability to efficiently transmit between people, therefore sustained human-to-human transmission is thus currently considered unlikely.  


3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?  

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

-- If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


A(H9N2), China 

-- Since the last risk assessment of 25 August 2025, eight human cases of infection with A(H9N2) influenza viruses were notified to WHO from China between 5 and 8 September 2025. 

-- All but one of the cases were in children and were reported from Anhui (1), Chongqing (1), Guangdong (1), Guangxi (2), Hunan (1), Sichuan (1) and Tianjin (1). 

-- Four had onsets of symptoms in February and were retrospectively reported. Two had onsets in July and two had onsets in August. All but one had known exposure to either live poultry markets or backyard poultry

-- Five cases had mild illness and three cases developed pneumonia and were hospitalized and recovered. 

-- No further cases were detected among contacts of these cases.   


Risk Assessment for avian influenza A(H9N2):   

1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?   

-- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. 

-- Most human infections of A(H9N2) to date have resulted in mild clinical illness. Since the virus is endemic in poultry in multiple countries in Africa and Asia{11}, further human cases associated with exposure to infected poultry are expected but remain unusual. 

-- The impact to public health if additional sporadic cases are detected is minimal. 

-- The overall global public health risk of additional sporadic human cases is low.  


2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses related to this event?   

-- At the present time, no sustained human-to-human transmission has been identified associated with the recent reported human infections with A(H9N2) viruses. 

-- Current evidence suggests that influenza A(H9N2) viruses from these cases did not acquire the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.   


3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?   

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

-- If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.   


Swine influenza viruses in humans  

Influenza A(H1N1)v, Germany 

Since the last risk assessment of 25 August 2025, the detection of an influenza A(H1N1)v virus in a human was reported from Germany. 

-- The virus from this case was sequenced and had an HA belonging to clade 1C.2.2, similar to other 1C.2.2 viruses detected in swine in the region. 


Risk Assessment:  

1. What is the public health risk of additional human cases of infection with swine influenza viruses?  

-- Swine influenza viruses circulate in swine populations in many regions of the world. 

-- Depending on geographic location, the genetic characteristics of these viruses differ. 

-- Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. 

-- Human infection tends to result in mild clinical illness in most cases. 

-- Since these viruses continue to be detected in swine populations, further human cases are expected but remain unusual. 

-- The impact to public health if additional sporadic cases are detected is minimal. The overall risk of additional sporadic human cases is low.  


2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?   

-- No sustained human-to-human transmission was identified associated with the event described above. 

-- Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.  


3. What is the likelihood of international spread of swine influenza viruses by travelers?   

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

-- If this were to occur, further community level spread is considered unlikely as current evidence suggests that these viruses have not acquired the ability to transmit easily among humans. 


For more information on zoonotic influenza viruses, see the report from the WHO Consultation on the Composition of Influenza Virus Vaccines for Use in the 2026 Southern Hemisphere Influenza Season that was held on 22-25 September 2025 at this link. 


Overall risk management recommendations

-- Surveillance and investigations 

- Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. 

- Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. 

- Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. 

- WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses. 

- As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. 

- Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

- Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.9 More guidance can be found from WOAH and FAO. 

- When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. 

- Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

- Vigilance for the emergence of novel influenza viruses with pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. 


Notifying WHO 

All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{10} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{11} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{12}. 

Evidence of illness is not required for this report. 

- WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions


Virus sharing and risk assessment 

- It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza reference laboratories. 

- Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{13} with a WHO Collaborating Centre for influenza of GISRS. 

- The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

- The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. 

- TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


Risk reduction 

- Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

- Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

- WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


Trade and travellers 

- WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. 

- Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

- WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. 

- For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

-- WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

-- WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

-- WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

-- WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

-- Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

-- Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

-- World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

-- Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

-- OFFLU http://www.offlu.org/ 

___

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).   

{7} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{8} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{9} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/

{10} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).    

{11} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518 

{12} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850 

{13} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/259402

___

Source: World Health Organization, https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--29-september-2025

____

My New Space

Most Popular Posts